Abstract
Cerebrospinal fluid (CSF) biomarkers (protein tau, phosphorylated tau and amyloid Beta 1–42) are recognized as a supportive feature in diagnosis of Alzheimer’s disease (AD) and their role in identifying atypical variants of AD is currently under investigation. We dosed these proteins in nine patients clinically and instrumentally affected by posterior cortical atrophy (PCA), a rare disorder characterized by a progressive neurodegenerative process that involves primarily the posterior brain regions. We compared the obtained values with a large group of AD patients (N = 117), recruited in our neurological department. Our data revealed no differences in the CSF profile between PCA and AD, showing abnormal values of protein tau, phosphorylated tau and amyloid Beta 1–42 in both groups of patients. This study underlines the diagnostic importance of CSF biomarkers in PCA patients, supporting the hypothesis that PCA is an atypical variant of AD with an onset before the age of 65.
This is a preview of subscription content, log in via an institution to check access.
References
Migliaccio R, Agosta F, Possin KL, Rabinovici GD, Miller BL, Gorno-Tempini ML (2012) White matter atrophy in Alzheimer’s disease variants. Alzheimers Dement 8(5 Suppl):S78–87.e1–2
Migliaccio R, Agosta F, Rascovsky K, Karydas A, Bonasera S, Rabinovici GD, Miller BL, Gorno-Tempini ML (2009) Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 73(19):1571–1578
Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC (2012) Posterior cortical atrophy. Lancet Neurol 11(2):170–178
Maillet D, Moroni C, Belin C (2009) Posterior cortical atrophy. Psychol Neuropsychiatr Vieil 7(3):193–203
Rosén C, Zetterberg H (2013) Cerebrospinal fluid biomarkers for pathological processes in Alzheimer’s disease. Curr Opin Psychiatry 26(3):276–282
Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Bibl M (2009) Combined CSF tau, p-tau181 and amyloid-b 38/40/42 for diagnosing Alzheimer’s disease. J Neural Transm 116:203–212
Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, Hodges JR (2007) Focal cortical presentation of Alzheimer’s disease. Brain 130(Pt 10):2636–2645
Formaglio M, Costes N, Seguin J, Tholance Y, Le Bars D, Roullet-Solignac I, Mercier B, Krolak-Salmon P, Vighetto A (2011) In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings. J Neurol 258(10):1841–1851
Seguin J, Formaglio M, Perret-Liaudet A, Quadrio I, Tholance Y, Rouaud O, Thomas-Anterion C, Croisile B, Mollion H, Moreaud O, Salzmann M, Dorey A, Bataillard M, Coste MH, Vighetto A, Krolak-Salmon P (2011) CSF biomarkers in posterior cortical atrophy. Neurology 76(21):1782–1788
Baumann TP, Duyar H, Sollberger M, Kuhle J, Regeniter A, Gomez-Mancilla B, Schmidtke K, Monsch AU (2010) CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy. Dement Geriatr Cogn Disord 29(6):530–533
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Coppi, E., Ferrari, L., Santangelo, R. et al. Further evidence about the crucial role of CSF biomarkers in diagnosis of posterior cortical atrophy. Neurol Sci 35, 785–787 (2014). https://doi.org/10.1007/s10072-014-1644-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-014-1644-5